13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001440771
Total reported value
$177.3M
$177.3M
38 檔
48.2%
During the Q3 2024 filing period, Stonepine Capital Management, LLC (CIK: 0001440771) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $177.3M across 38 reported positions.
In Q3 2024, Stonepine Capital Management, LLC displayed an active expansion posture, initiating 17 new positions and adding to 12 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | Stock-Healthcare | 23.62% | +1.16% | — | |
| 2 | EOLS | Evolus Inc | Stock-Other | 14.02% | +4.41% | -17.36% | |
| 3 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 8.71% | — | -1.31% | |
| 4 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 3.87% | — | — | |
| 5 | RPRX | Royalty Pharma plc | Stock-Healthcare | 3.79% | — | — | |
| 6 | XOMA | Xoma Royalty Corporation | Stock-Other | 3.26% | -0.87% | EXIT | |
| 7 | RIGL | Rigel Pharmaceuticals Inc | Stock-Other | 3.16% | — | +1.34% | |
| 8 | ZVRA | Zevra Therapeutics Inc | Stock-Other | 3.07% | +0.30% | — | |
| 9 | ANIK | Anika Therapeutics Inc | Stock-Other | 2.95% | — | +14.46% | |
| 10 | RVNCEUR | Revance Therapeutics Inc | Stock-Other | 2.69% | — | -70.71% | |
| 11 | IRWD | Ironwood Pharmaceuticals Inc | Stock-Other | 2.60% | — | +1982.81% | |
| 12 | VSTM | Verastem Inc | Stock-Other | 2.48% | +0.21% | — | |
| 13 | ✓ | Optinose Inc | Stock-Other | 2.41% | — | +142.07% | |
| 14 | URGN | UroGen Pharma Ltd. | Stock-Other | 2.25% | — | — | |
| 15 | SCPH | Scpharmaceuticals Inc | Stock-Other | 2.24% | — | +84.70% | |
| 16 | ✓ | Establishment Labs Holdings In | Stock-Other | 2.05% | -1.27% | EXIT | |
| 17 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 1.91% | -0.89% | EXIT | |
| 18 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.81% | — | — | |
| 19 | ACRS | Aclaris Therapeutics Inc | Stock-Other | 1.79% | — | +27.57% | |
| 20 | TELA | Tela Bio Inc | Stock-Other | 1.77% | +0.48% | +77.42% | |
| 21 | INDV | Indivior Pharmaceuticals, Inc. | Stock-Other | 1.66% | — | — | |
| 22 | XGN | Exagen Inc | Stock-Other | 1.04% | — | +48.98% | |
| 23 | MIST | Milestone Pharmaceuticals In | Stock-Other | 0.96% | — | -19.32% | |
| 24 | SRZN | Surrozen Inc | Stock-Other | 0.83% | -0.38% | EXIT | |
| 25 | AYTU | Aytu Biopharma Inc | Stock-Other | 0.74% | +0.24% | +6.03% | |
| 26 | ✓ | Stock-Other | 0.73% | — | +41.97% | ||
| 27 | TORCEUR | Adicet Bio Inc | Stock-Other | 0.55% | — | — | |
| 28 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.52% | — | — | |
| 29 | FNAUSD | Paragon 28 Inc | Stock-Other | 0.48% | — | — | |
| 30 | KPRX | Kiora Pharmaceuticals Inc | Stock-Other | 0.47% | — | — | |
| 31 | ✓ | Polypid LTD | Stock-Other | 0.30% | — | — | |
| 32 | TSVT* | 2seventy Bio Inc | Stock-Other | 0.30% | — | — | |
| 33 | MYO | Myomo Inc | Stock-Other | 0.25% | — | — | |
| 34 | APRE | Aprea Therapeutics Inc | Stock-Other | 0.24% | — | — | |
| 35 | 2662247D | Iteos Therapeutics Inc | Stock-Other | 0.19% | — | — | |
| 36 | TENX | Tenax Therapeutics Inc | Stock-Other | 0.11% | -0.82% | — | |
| 37 | RYI | Viracta Therapeutics Inc | Stock-Other | 0.07% | — | — | |
| 38 | ✓ | Alimera Sciences Inc Cvr | Stock-Other | 0.06% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | ADMA | Adma Biologics Inc | +4.6% | — | Unchanged |
| 2 | JAZZ | Jazz Pharmaceuticals plc | +3.9% | NEW | New buy |
| 3 | RPRX | Royalty Pharma plc | +3.8% | NEW | New buy |
| 4 | ZVRA | Zevra Therapeutics Inc | +3.1% | NEW | New buy |
| 5 | VSTM | Verastem Inc | +2.5% | NEW | New buy |
| 6 | IRWD | Ironwood Pharmaceuticals Inc | +2.3% | +1982.81% | Add |
| 7 | URGN | UroGen Pharma Ltd. | +2.3% | NEW | New buy |
| 8 | ✓ | Establishment Labs Holdings In | +2.1% | NEW | New buy |
| 9 | ACAD | Acadia Pharmaceuticals Inc | +1.8% | +3837.90% | Add |
| 10 | DAWNGBX | Day One Biopharmaceuticals I | +1.8% | NEW | New buy |
| 11 | INDV | Indivior Pharmaceuticals, Inc. | +1.7% | NEW | New buy |
| 12 | RIGL | Rigel Pharmaceuticals Inc | +0.9% | +1.34% | Add |
| 13 | SCPH | Scpharmaceuticals Inc | +0.6% | +84.70% | Add |
| 14 | ARQT | Arcutis Biotherapeutics Inc | +0.5% | NEW | New buy |
| 15 | FNAUSD | Paragon 28 Inc | +0.5% | NEW | New buy |
| 16 | KPRX | Kiora Pharmaceuticals Inc | +0.5% | NEW | New buy |
| 17 | XGN | Exagen Inc | +0.4% | +48.98% | Add |
| 18 | ✓ | Polypid LTD | +0.3% | NEW | New buy |
| 19 | MYO | Myomo Inc | +0.3% | NEW | New buy |
| 20 | 2662247D | Iteos Therapeutics Inc | +0.2% | NEW | New buy |
| 21 | ✓ | Optinose Inc | +0.2% | +142.07% | Add |
| 22 | SRZN | Surrozen Inc | +0.2% | +66.45% | Add |
| 23 | ✓ | +0.2% | +41.97% | Add | |
| 24 | TENX | Tenax Therapeutics Inc | +0.1% | NEW | New buy |
| 25 | RYI | Viracta Therapeutics Inc | +0.1% | NEW | New buy |
| 26 | ✓ | Alimera Sciences Inc Cvr | +0.1% | NEW | New buy |
| 27 | TSVT* | 2seventy Bio Inc | -0.1% | — | Unchanged |
| 28 | TORCEUR | Adicet Bio Inc | -0.1% | — | Unchanged |
| 29 | ACRS | Aclaris Therapeutics Inc | -0.1% | +27.57% | Add |
| 30 | APRE | Aprea Therapeutics Inc | -0.3% | — | Unchanged |
| 31 | ETON | Eton Pharmaceuticals Inc | -0.3% | EXIT | Sold out |
| 32 | AYTU | Aytu Biopharma Inc | -0.5% | +6.03% | Add |
| 33 | MIST | Milestone Pharmaceuticals In | -0.5% | -19.32% | Trim |
| 34 | EYEGEUR | Kiora Pharmaceuticals Inc | -0.8% | EXIT | Sold out |
| 35 | ANIK | Anika Therapeutics Inc | -0.9% | +14.46% | Add |
| 36 | TELA | Tela Bio Inc | -0.9% | +77.42% | Add |
| 37 | AUPH | Aurinia Pharmaceuticals Inc | -1.6% | EXIT | Sold out |
| 38 | XOMA | Xoma Royalty Corporation | -2.2% | -22.00% | Trim |
| 39 | LKFT | Lakefront Biotherapeutic-adr | -2.3% | -1.31% | Trim |
| 40 | EOLS | Evolus Inc | -2.4% | -17.36% | Trim |
| 41 | RVNCEUR | Revance Therapeutics Inc | -3.9% | -70.71% | Trim |
| 42 | ✓ | Alimera Sciences Inc | -17.8% | EXIT | Sold out |
According to official SEC Form 13F filings, Stonepine Capital Management, LLC reported a total U.S. public equity portfolio value of $177.3M across 38 disclosed positions in Q3 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including ADMA, EOLS, LKFT) accounted for 48.2% of total reported equity market value during Q3 2024.
Top New Position Initiated
JAZZ
市值: $6.1M
Top Position Liquidated / Trimmed
ALIMERA SCIENCES INC
前期市值: $19.5M
During Q3 2024, Stonepine Capital Management, LLC's top holdings by market value included ADMA (23.6%)、EOLS (14.0%)、LKFT (8.7%). The largest single position, ADMA, represented 23.6% of total portfolio value.
In Q3 2024, Stonepine Capital Management, LLC made 38 total portfolio adjustments, initiating 17 new buys, adding to 12 positions, trimming 5 holdings, and fully liquidating 4 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.